Heather Loryn Platt

Dr. Heather Loryn Platt


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2022 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
HPHeather Loryn Platt
Heather Loryn Platt
TOTosin Omole
Tosin Omole
JCJose Cardona
Jose Cardona
NFNeil J Fraser
Neil J Fraser
RMRichard A Mularski
Richard A Mularski
LMLuwy Musey
Luwy Musey

1 July 2024 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
HPHeather Loryn Platt
Heather Loryn Platt
CBChristopher Bruno
Christopher Bruno
EBErik Buntinx
Erik Buntinx
EPEnrique Pelayo
Enrique Pelayo
DGDiego Garcia-Huidobro
Diego Garcia-Huidobro
SGSTRIDE-3 Study Group
STRIDE-3 Study Group

26 May 2020 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Open access
FGfor the V114-008 Study Group
for the V114-008 Study Group
HPHeather Loryn Platt
Heather Loryn Platt
DGDavid Greenberg
David Greenberg
BTBruce Tapiero
Bruce Tapiero
RCRobert A. Clifford
Robert A. Clifford
LMLuwy K. Musey
Luwy K. Musey
Background: Pneumococcal disease remains a public health priority worldwide. This phase 2 study (V114-008; NCT02987972; EudraCT 2016-001117-25) compared safety and immunogenicity of 2 clinical lots of V114 (investigational 15-valent pneumococcal vaccine: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 22F*, 23F, 33F*) to 13-valent pneumococcal conjugate vaccine (PCV13) in healthy infants (*serotypes unique to V114). Methods: Healthy infants 6–12 weeks old were randomized to receive a 4-dose regimen of V114 Lot 1, V114 Lot 2 or PCV13 at 2, 4, 6 and 12–15 months old. Adverse events were evaluated after each dose. Primary immunogenicity endpoint was to demonstrate noninferiority of V114 Lot 1 and V114 Lot 2 relative to PCV13 based on proportion of infants achieving serotype-specific IgG concentration ≥0.35 µg/mL for 13 serotypes shared with PCV13 at 1 month postdose 3 (PD3). Serotype-specific IgG geometric mean concentrations (GMCs) for all 15 V114 serotypes were measured at PD3, predose 4 and 1 month postdose 4 (PD4). Results: Overall, 1044 of 1051 randomized infants received ≥1 dose of vaccine (V114 Lot 1 [n = 350], V114 Lot 2 [n = 347] or PCV13 [n = 347]). Adverse events were generally comparable across groups. At PD3, both V114 lots met noninferiority criteria for all 13 serotypes shared with PCV13. IgG GMCs were comparable among V114 and PCV13 recipients at PD3 and PD4. Serotype 3 responses were higher following receipt of V114 than PCV13. Both V114 lots induced higher GMCs than PCV13 to the 2 unique V114 serotypes. Conclusions: Immunogenicity of both V114 lots was noninferior to PCV13 for all 13 shared serotypes between the 2 vaccines and displayed comparable safety and tolerability profiles to PCV13.

31 July 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
PSPaul Scott
Paul Scott
MHMiwa Haranaka
Miwa Haranaka
JCJung Hyun Choi
Jung Hyun Choi
HSHelen Stacey
Helen Stacey
MDMarc Dionne
Marc Dionne
HPHeather Loryn Platt
Heather Loryn Platt
Background: Pneumococcal diseases cause considerable morbidity and mortality in adults. V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) specifically designed to protect adults from pneumococcal serotypes responsible for the majority of residual pneumococcal diseases. This phase 3 study evaluated safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine–experienced adults aged ≥50 years. Methods: A total of 717 adults were enrolled to receive a single dose of pneumococcal vaccine as follows: cohort 1 (n = 350) previously received 23-valent pneumococcal polysaccharide vaccine (PPSV23) and were randomized 2:1 to receive V116 or PCV15, respectively; cohort 2 (n = 261) previously received PCV13 and were randomized 2:1 to receive V116 or PPSV23, respectively; cohort 3 (n = 106) previously received PPSV23 + PCV13, PCV13 + PPSV23, PCV15 + PPSV23, or PCV15 and all received open-label V116. Immunogenicity was evaluated 30 days postvaccination using opsonophagocytic activity (OPA) geometric mean titers (GMTs) and immunoglobulin G (IgG) geometric mean concentrations (GMCs) for all V116 serotypes. Safety was evaluated as the proportion of participants with adverse events (AEs). Results: V116 was immunogenic across all 3 cohorts as assessed by serotype-specific OPA GMTs and IgG GMCs postvaccination for all 21 serotypes. V116 elicited comparable immune responses to serotypes shared with PCV15 (cohort 1) or PPSV23 (cohort 2), and higher immune responses to serotypes unique to V116. The proportions of participants with solicited AEs were generally comparable across cohorts. Conclusions: V116 is well tolerated with a safety profile comparable to currently licensed pneumococcal vaccines and generates IgG and functional immune responses to all V116 serotypes, regardless of prior pneumococcal vaccine received. Clinical Trials Registration: NCT05420961; EudraCT 2021-006679-41.

28 August 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
KFKristen Feemster
Kristen Feemster
WHWilliam Hausdorff
William Hausdorff
NBNatalie Banniettis
Natalie Banniettis
HPHeather Loryn Platt
Heather Loryn Platt
PVPriscilla T Velentgas
Priscilla T Velentgas
UBUlrike K Kirsten Buchwald
Ulrike K Kirsten Buchwald
Pneumococcal vaccines are a cornerstone for the prevention of pneumococcal diseases, reducing morbidity and mortality in children and adults worldwide. Pneumococcal vaccine composition is based on the polysaccharide capsule of Streptococcus pneumoniae, which is one of the most important identified contributors to the pathogen’s virulence. Similarities in the structural composition of polysaccharides included in licensed pneumococcal vaccines may result in cross-reactivity of immune response against closely related serotypes, including serotypes not included in the vaccine. Therefore, it is important to understand whether cross-reactive antibodies offer clinical protection against pneumococcal disease. This review explores available evidence of cross-reactivity and cross-protection associated with pneumococcal vaccines, the challenges associated with the assessment of cross-reactivity and cross-protection, and implications for vaccine design and development.

14 April 2025 in Vaccine
Verified
Journal Article
Closed access
RJR. Joshi
R. Joshi
HAH.T. Ayele
H.T. Ayele
KJKell Johnson
Kell Johnson
PVPriscilla T Velentgas
Priscilla T Velentgas
HPHeather Loryn Platt
Heather Loryn Platt
PSP. Saddier
P. Saddier